Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Malnutrition 2Head and Neck Neoplasms 2Colorectal Neoplasms 2Thrombosis 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sexuality 1Sexual Dysfunction, Physiological 1Salivary Gland Neoplasms 1Radiation Injuries 1Protein Metabolism 1Polycystic Ovary Syndrome 1Pain 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Multiple Endocrine Neoplasia Type 1 1Mucositis 1Meningioma 1Hemorrhage 1Glioblastoma 1Erectile Dysfunction 1Disease 1Diabetes Insipidus 1Brain Neoplasms 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × Arginine × Clear all
NCT03478358 2022-08-31

Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors

Peking Union Medical College Hospital

Phase 1 Unknown
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡